AMLX - Amylyx Pharmaceuticals Class Action Lawsuit News – Seek Counsel Potential to Make Claim Recover Losses Contact Johnson Fistel LLP (AMLX) | Benzinga
SAN DIEGO, March 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx " or the "Company"). Join the Amylyx class action lawsuit to potentially recover losses. Johnson Fistel LLP, a top law firm, can help you become the lead plaintiff. Stay updated on the lawsuit by checking for the latest news. SUBMIT YOUR INFORMATION NOW!
The class action is on behalf of shareholders who purchased or otherwise acquired securities between November 11, 2022 to November 8, 2023. Investors have until April 9, 2024, to move the Court to serve as lead plaintiff in this action.
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) defendants had overstated RELYVRIO's (a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol, for the treatment ...
AMLX)>Full story available on Benzinga.com